Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC-GA Trial: Neoadjuvant gemcitabine + nab-paclitaxel for borderline resectable pancreatic cancer
jRCTs051180104Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2016
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel and gemcitabine in pancreatic cancer (PC), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Overall survival. Started Oct 2016; status: completed.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs051180104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180104.